“ADA 2026 GLP-1 Pipeline: Retatrutide, CagriSema, Orforglipron The Next Wave of Incretin Therapies Unveiled in New Orleans”. Diabzen 4, no. 23 (July 7, 2026): 46–47. Accessed July 28, 2026. https://thediabzen.com/index.php/d/article/view/66.